Playback speed
Share post
Share post at current time

Paul S. Mischel, MD – Brain Cancer Science Talk (Episode 5)

ecDNA, the Importance of Science, #Data and Collaboration, and Upgrading Science in Neuro-Oncology

Click here for Paul Mischel’s “Meet the Team” profile on MissionGBM

It is our pleasure to share one of the most eagerly anticipated MissionGBM “Brain Cancer Science Talk” video interviews.  Dr. Mischel is the Fortinet Founders Professor and Professor, by courtesy, of Neurosurgery, Stanford University School of Medicine

Paul and I have spent countless hours together over more than 2 years reviewing #Data, talking about innovative, evidence-based treatment strategies for brain cancer, and catalyzing translational research to create such treatment options.

It isn’t work if you love what you are doing…and we love what we are doing.

We begin by talking about the discovery of ecDNA, its role in oncogenesis, and potential strategies for clamping ecDNA to limit its cancer-promoting characteristics.  Next, we move on to a discussion of Paul’s work to identify fluoxetine (Prozac®) as a molecularly-targeted treatment for GBM/HGGs that are dependent on specific lipid structures in the cellular membrane to grow rapidly (see here).  We discuss the role of the outstanding Innovative Medicines Accelerator at Stanford University (see here) as a leading example of a model focused on translating basic academic research into promising and well-developed clinical candidates.

Finally, we chat about the pressing need to upgrade rigorous science in the field of Neuro-Oncology, and we suggest a new model for training Neuro-Oncologists that we believe will improve the probability of success of drug development, patient care, and more importantly, spare brain cancer patients from enrollment in clinical trials that have little scientific basis to recommend them.


N-of-1 on Behalf of All